Detalles de la búsqueda
1.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35263519
2.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139274
3.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Lancet Oncol
; 25(3): 317-325, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38342115
4.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882206
5.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38112922
6.
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
BMC Cancer
; 24(1): 641, 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38789924
7.
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
J Natl Compr Canc Netw
; 22(2): 99-107, 2024 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38437792
8.
Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
Future Oncol
; 20(6): 335-348, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37602372
9.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493792
10.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32101663
11.
Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 201(2): 307-316, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37418031
12.
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
BMC Cancer
; 23(1): 792, 2023 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37612624
13.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30786188
14.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34860318
15.
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 195(2): 127-139, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35545724
16.
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Future Oncol
; 18(33): 3701-3711, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36135712
17.
Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
Breast Cancer Res Treat
; 187(3): 903-913, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33649981
18.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Breast Cancer Res Treat
; 188(1): 179-190, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33641083
19.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
J Natl Compr Canc Netw
; : 1-8, 2021 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761455
20.
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
Breast Cancer Res
; 22(1): 114, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109210